Define “product hopping” in the Federal Trade Commission Act and establish a statutory framework for the Federal Trade Commission’s (FTC’s) litigation authority against manufacturers that engage in such practices
Allow FTC to impose civil penalties and seek other appropriate relief in district court from parties that violate antitrust law in this area
Limit the number of patents that can be litigated under some provisions of the Biologics Price Competition and Innovation Act of 2009
Impose a private sector mandate by limiting the number of patents that may be asserted in infringement claims for a small number of biological products
Estimated budgetary effects would stem from
Generic or biosimilar drugs entering the market earlier, on average, than would be the case under current law, resulting in lower federal spending for prescription drugs and subsidies for health insurance
